Analyst Ratings for INmune Bio Inc. (INMB)
INMB Rating Summary
INMB Price Target Summary
- Highest: $9.00 (Lucid Capital Markets)
- Lowest: $0.60 (Scotiabank)
- Average: $5.87
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$5.87 (+380.9%)
* Over Last 12-Mos
Rating Score: 6.4 / 10
Percentile Rank: 67%
Rating Score: 6.4 / 10
Percentile Rank: 67%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/11/2026 | Lucid Capital Markets | Elemer Piros | Upgrade | Buy (Neutral) |
9.00 (N/A) |
1.28 (1.22) |
-4.69% | Details |
| 7/1/2025 | Scotiabank | George Farmer | Downgrade | Sector Underperform (Sector Outperform) |
0.60 (23.00) |
5.33 (1.22) |
-77.11% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
